G01N 2333/161
Gag-pol
Official title: gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
G01N2333/161 (Gag-pol) appears on 43 US grants and 69 published applications in this corpus.
Search patents in G01N- Granted patents
- 43
- Published applications
- 69
- Assignees
- 59
- Inventors
- 154
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 2 |
| 2004 | 1 | 1 |
| 2005 | 0 | 7 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 4 |
| 2009 | 2 | 2 |
| 2010 | 2 | 7 |
| 2011 | 1 | 2 |
| 2012 | 2 | 5 |
| 2013 | 2 | 2 |
| 2014 | 1 | 5 |
| 2015 | 1 | 2 |
| 2016 | 2 | 3 |
| 2017 | 5 | 5 |
| 2018 | 4 | 6 |
| 2019 | 4 | 2 |
| 2020 | 5 | 3 |
| 2021 | 2 | 3 |
| 2022 | 3 | 2 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-human immunodeficiency virus-1 antibodies and methods for uses thereof29 Sep 2026US 12,747,285 B2Grifols Diagnostic Solutions Inc.
- Exosome-mediated diagnosis of hepatitis virus infections and diseases6 Jan 2026US 12,517,129 B2Morehouse School of Medicine
- Exosome-mediated diagnosis of hepatitis virus infections and diseases14 Jun 2022US 11,360,090 B2Morehouse School of Medicine
- Exosome-mediated diagnosis of human immunodeficiency virus infection12 Apr 2022US 11,300,565 B2Morehouse School of Medicine
- Virus-like particle (VLP) based small molecule-protein interaction trap25 Jan 2022US 11,231,416 B2Universiteit Gent
- Antibody against human immunodeficiency virus type 1 p24 and type 2 p26 and uses thereof30 Apr 2026US 2026/0118359 A1Hytest Ltd.
- N-terminal multifunctional conjugation of proteins and peptides (for biosensing)26 Mar 2026US 2026/0086097 A1Roswell Biotechnologies, Inc.
- Luminescent based antigen assay31 Oct 2024US 2024/0361321 A1
- Anti-human immunodeficiency virus-1 antibodies and methods for uses thereof18 Jul 2024US 2024/0239876 A1Grifols Diagnostic Solutions Inc.
- Rapid quantitative assay to assess duration of infection28 Dec 2023US 2023/0417745 A1Sedia Biosciences Corporation
Most cited
By later US patents
- Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase152US 5,503,978 AUniversity Research Corporation · 1996
- High affinity ssDNA ligands of HIV-1 reverse transcriptase113US 5,786,462 ANeXstar Pharmaceuticals, Inc. · 1998
- Process for determination of the activity of a substance using an in vitro functional test25US 6,818,396 B1Proteus S.A. · 2004
- Chemiluminescent immunoassay for detection of antibodies to various viruses6US 6,203,974 B1Abbott Laboratories · 2001
- Neutralizing GP41 antibodies and their use4US 9,475,862 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2016